Regulatory Bayer wins MHRA approval for Kerendia in heart failure PharmaTimesNew authorisation offers additional option for patients with lvef 40%RegulatoryCardiovascularRead full story pharminent April 13, 2026 (Last updated: April 13, 2026) PharmaTimes New authorisation offers additional option for patients with lvef 40% RegulatoryCardiovascularRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Oricell closes a ‘pre-IPO’ megaround to aim CAR-T at solid tumorsNext: FDA hands another rejection to Replimune’s melanoma therapy Related Stories Regulatory Outlook Therapeutics Secures FDA Approval for LYTENAVA pharminent July 31, 2026 Regulatory Outlook finally claims FDA approval for AMD drug pharminent July 27, 2026 Regulatory Outlook Therapeutics wins FDA approval for Lytenava in wet AMD pharminent July 27, 2026
